IL37 and palmoplantar pustulosis: In contrast, a phase-3 clinical trial in Japan with 159 patients with PPP investigating guselkumab, a human IgG1 monoclonal antibody targeting the p19 subunit of IL-23, demonstrated efficacy in PPP.27